STOCK TITAN
  1. Home
  2. SEC-Filings
  3. QLI

Qilian International Holding Group Ltd. Ordinary Shares SEC Filings

QLI NASDAQ

Welcome to our dedicated page for Qilian International Holding Group Ltd. Ordinary Shares SEC filings (Ticker: QLI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Spotting licorice supply risks, heparin price swings or China-specific regulations in Qilian International Holding Group Ltd. filings can feel like searching for a needle in a 300-page stack of disclosures. Add cross-referenced footnotes and you have a genuine research headache.

Stock Titan ends that struggle. Our AI reads every Qilian International Holding Group insider trading Form 4 transactions, decodes each Qilian International Holding Group quarterly earnings report 10-Q filing, and delivers the meaning in plain English. Whether you need the latest Qilian International Holding Group Form 4 insider transactions real-time alert or a quick brief on an 8-K material event, the platform surfaces what matters and links you straight to the original exhibit.

Here’s how professional investors use the page every day:

  • AI-powered summaries that explain complex risks—Qilian International Holding Group SEC filings explained simply
  • Real-time push when a director buys shares—Qilian International Holding Group executive stock transactions Form 4
  • Trend snapshots from each Qilian International Holding Group earnings report filing analysis
  • Side-by-side redlines of the Qilian International Holding Group annual report 10-K simplified
  • Proxy highlights covering Qilian International Holding Group proxy statement executive compensation
  • Context for sudden news via Qilian International Holding Group 8-K material events explained

From segment revenue shifts in pharmaceuticals to cost variables in oxytetracycline production, Stock Titan’s expert analysis translates QLI’s raw disclosures into actionable insights—saving you hours and helping you make informed decisions faster.

Filing

[6-K] Qilian International Holding Group Ltd. Ordinary Shares Current Report (Foreign Issuer)

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report

FAQ

What is the current stock price of Qilian International Holding Group Ltd. Ordinary Shares (QLI)?

The current stock price of Qilian International Holding Group Ltd. Ordinary Shares (QLI) is $6.03 as of August 9, 2024.

What is the market cap of Qilian International Holding Group Ltd. Ordinary Shares (QLI)?

The market cap of Qilian International Holding Group Ltd. Ordinary Shares (QLI) is approximately 38.7M.

What are the primary business segments of Qilian International Holding Group Ltd.?

The company operates across various segments including pharmaceutical manufacturing, chemical processing, traditional Chinese medicine derivatives, licorice-based products, and ancillary items such as sausage casings and fertilizers. Each segment is designed to cater to specific market needs while contributing to a diversified revenue model.

How does Qilian International adapt to changing market conditions?

Qilian has strategically reduced investments in areas facing declining demand while increasing focus on higher-potential segments like heparin sodium and licorice products. This proactive reallocation of resources demonstrates the company’s commitment to risk management and operational efficiency.

What products does Qilian International manufacture?

The company manufactures a diverse array of products, including oxytetracycline, heparin sodium, licorice extracts, traditional Chinese medicine derivatives, sausage casings, and fertilizers. This wide range helps them serve various industrial and healthcare sectors.

How is Qilian positioning itself in the competitive pharmaceutical and chemical market?

Qilian leverages integrated production capabilities, advanced research and development, and strategic diversification to maintain competitiveness. The focus on quality and operational excellence is central to its market positioning.

What strategies has Qilian implemented to manage production costs?

In response to increasing production costs and falling market demand in certain segments, Qilian has decreased investment in oxytetracycline and shifted focus towards products with promising market prospects, such as heparin sodium and licorice derivatives. This approach helps control costs and aligns production with market demand.

Does Qilian have any involvement in financial and software development sectors?

Yes, Qilian has diversified its investments by venturing into financial products, wealth management, and software development. These initiatives are part of a broader strategy to enhance overall business efficiency and support diversified growth.

What is the geographical scope of Qilian International’s operations?

The company primarily operates within China, with its products marketed across more than 20 provinces. Its operational focus and significant production capabilities position it as a key player in the regional pharmaceutical and chemical industries.

How can investors view Qilian’s business model and risk management strategies?

Investors can observe that Qilian proactively manages market risks by continuously reshaping its product portfolio and investments in response to market fluctuations. Its diversified business model and commitment to R&D make its approach methodical and grounded in industry expertise.
Stock QLI logo
Qilian International Holding Group Ltd. Ordinary Shares

NASDAQ:QLI

QLI Rankings

#5226 Ranked by Market Cap
N/A Ranked by Dividends

QLI Stock Data

38.68M
7.15M
77.45%
0.04%
0.4%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
China
Jiuquan